ABSTRACT
Natural killer (NK) cells are important immune cells in the organism and are the third major type of lymphocytes besides T cells and B cells, which play an important function in cancer therapy. In addition to retaining the tumor cell killing function of natural killer cells, natural killer cell-derived exosomes cells also have the characteristics of high safety, wide source, easy to preserve and transport. At the same time, natural killer cell-derived exosomes are easy to modify, and the engineered exosomes can be used in combination with a variety of current cancer therapies, which not only enhances the therapeutic efficacy, but also significantly reduces the side effects. Therefore, this review summarizes the source, isolation and modification strategies of natural killer cell-derived exosomes and the combined application of natural killer cell-derived engineered exosomes with other antitumor therapies, which is expected to accelerate the clinical translation process of natural killer cell-derived engineered exosomes in cancer therapy.
Subject(s)
Exosomes , Killer Cells, Natural , Neoplasms , Humans , Clinical Relevance , Exosomes/metabolism , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Neoplasms/therapy , Neoplasms/immunology , Neoplasms/metabolism , Neoplasms/pathologyABSTRACT
The discovery and use of exosomes ushered in a new era of cell-free therapy. Exosomes are a subgroup of extracellular vesicles that show great potential in disease treatment. Engineered exosomes. with their improved functions have attracted intense interests of their application in translational medicine research. However, the technology of engineering exosomes still faces many challenges which have been the great limitation for their clinical application. This review summarizes the current status of research on engineered exosomes and the difficulties encountered in recent years, with a view to providing new approaches and ideas for future exosome modification and new drug development.
ABSTRACT
The human induced pluripotent stem cell (iPSC) line SDQLCHi050-A was derived from the PBMCs of a healthy 5-year-old male child. The karyotyping, pluripotency, and trilineage differentiation characteristics were verified in the SDQLCHi050-A line.